Enzo Biochem

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. It operates through the following segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Therapeutics segment conducts research and development activities for therapeutic drug candidates. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in August 1976 and is headquartered in New York, NY.

NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company's executive compensation approach for the fiscal year ended July 31, 2020. To acknowledge and address the issues within the ISS report, Dr. Elazar Rabbani, the Company's Chairperson and CEO, has requested the Compensation Committee of the Company's Board of Directors not to pay his previously announced bonus in cash. In lieu thereof, he has requested such bonus be paid in common stock of Enzo based on the closing price of the Company's shares on the date of issuance. Mr. Barry Weiner, the Company's President, followed Dr. Rabbani's lead and made a similar request of the Compensation Committee. The Company stated the Compensation Committee has agreed to such requests and that Dr. Rabbani and Mr. Weiner have agreed to hold the common stock paid as bonus for at least three years post issuance.

ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES

CHEVY CHASE, Md., Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" or "the Company"), filed definitive proxy materials yesterday with the Securities and Exchange...

Roumell Asset Management Files Definitive Proxy Statement and Sends Letter to Enzo Biochem Shareholders

Enzo Biochem, Inc. has continued to underperform its peers and the general markets despite the tailwind from the pandemic outbreak. In November 2020, two investment funds went activist on the company, demanding the resignation of the CEO, adding new board directors, and the sale of the company.

Enzo Biochem: Betting On The Activists Now

Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment

Enzo Biochem, Inc. (ENZ) Q1 2021 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Wednesday , December 9 , 2020 at 4:30 pm (ET)

Enzo Biochem Reports First Quarter Fiscal 2021 Financial Results and Provides Business Update

Conference Call and Webcast Scheduled for December 9, 2020, 4:30 pm ET

Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been appointed to the Company's Board of Directors effective immediately.    

ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS

NEW YORK, NY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has been appointed to the company's Board of Directors effective immediately.   

ENZO BIOCHEM ANNOUNCES APPOINTMENT OF MARY TAGLIAFERRI, MD, TO ITS BOARD OF DIRECTORS

Direct-to-Consumer service will initially offer access to COVID-19 molecular and antibody testing and will expand to include other testing in the future

ENZO BIOCHEM LAUNCHES GOTESTMENOW™ ONLINE PLATFORM FOR CONSUMERS TO DIRECTLY ORDER COVID-19 LABORATORY TESTS

Enzo Biochem, Inc.'s (ENZ) on Q4 2020 Results - Earnings Call Transcript

Conference call and live webcast scheduled for today, Tuesday, October 13, 2020 at 4:30 pm (ET)

Enzo Biochem Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET

Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13

Enzo Biochem, Inc: Wildly Undervalued COVID-19 Test Play With Near-Term Catalysts

New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State New initiative introduces Enzo’s Independent Pharmacy Testing Program with full range of products and services to support rapid and accurate testing to more residents of New York State

ENZO BIOCHEM TO PROVIDE ACCESS TO COVID-19 TESTING AT MORE THAN 50 NY PHARMACIES IN COLLABORATION WITH CPESN NY

Shares of Enzo Biochem Inc. ENZ, +6.71% rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-19 diagnostic test.

Enzo Biochem shares rise on FDA authorization for coronavirus test

Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation

Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2

First Collaboration under Enzo’s School and Institution Testing (“SIT”) Program

Enzo Biochem to Provide COVID-19 Testing to Farmingdale State College  Staff and Students as They Return to Campus

Continues to Explore Opportunities for Use of the Compound as a Potential Treatment for COVID-19

Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I

Enzo Biochem, Inc. (ENZ) Q3 2020 Results - Earnings Call Transcript

NEW YORK, June  08, 2020  (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

Enzo Biochem Reports Third Quarter 2020 Financial Results

Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program

Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV-2 IgG Antibody Under FDA’s Emergency Use Authorization

NEW YORK, NY, April  29, 2020  (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof.  The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors. 

Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

Enzo Biochem, Inc. (NYSE: ENZ) shares were rallying Thursday following an update from the company on its comprehensive COVID-19 program.

Why Enzo Biochem Shares Are Rallying

NanoViricides

OPKO Health

Spherix

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagnostic tests, treatments and vaccines to combat the new coronavirus.

News for Enzo Biochem Stock (ENZ)